Biotech Values

[DewDiligence]

The interest in IL-28B is sufficiently recent that completed HCV studies with DAA’s have only haphazard data, at best, on the effect of the gene variants.

Also if you were a CC and had an 80% chance of SVR would they even use a DAA?

I do not understand your question—can you rephrase it?